Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
NCT ID: NCT07140211
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
9200 participants
INTERVENTIONAL
2025-09-30
2030-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery?
* compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
NCT06845423
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
NCT01828697
Low Molecular Weight hEparin vs. Aspirin Post-partum
NCT05058924
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
NCT07342127
Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women
NCT00745212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-molecular-weight heparin
Low-dose low-molecular-weight heparin
Low-molecular-weight heparin given for 7-10 days after delivery:
* enoxaparin 4000-6000IU o.d.
* nadroparin 3800-5700IU o.d.
* dalteparin 5000-7500IU o.d.
* tinzaparin 4500-7000IU o.d.
No treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-dose low-molecular-weight heparin
Low-molecular-weight heparin given for 7-10 days after delivery:
* enoxaparin 4000-6000IU o.d.
* nadroparin 3800-5700IU o.d.
* dalteparin 5000-7500IU o.d.
* tinzaparin 4500-7000IU o.d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility
Exclusion Criteria
* Any indication for therapeutic anticoagulation
* A high-risk of postpartum VTE
* An increased bleeding risk
* A contra-indication to heparin
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marc Blondon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marc Blondon
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-00622
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.